Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Inclusion Criteria: Cohort A: * Subjects who have completed the TQC3721-III-01 clinical trial, demonstrated good medication compliance during the 24-week treatment period as required by the protocol (with no major protocol deviations related to medication compliance), and experienced no treatment-related SAEs. * Sign the informed consent form and fully understand the trial content, procedures, and potential adverse reactions. * Willing and able to comply with the trial arrangements and to use the nebulizer correctly. * Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures. * Patients with a clear clinical history and related symptoms of COPD (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)). Cohort B: * Sign the informed consent form prior to screening and fully understand the trial content, procedures, and potential adverse reactions. * Willing and able to comply with the trial arrangements and to use the nebulizer correctly. * Aged between 40 and 80 years (inclusive), both male and female subjects are eligible. * Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures. * Patients with a clear clinical history a…